No abstract

Background: Trapa natans (Family: Trapacea) is basically an edible and ornate plant found in warm, temperate regions of Asia and Europe. Extracts of different parts, as well as the whole herb itself, have been found to traditionally use for the treating many ailments. Objective: Current review aims at documenting, finding research gap, and critically appraising the contemporary information of T. natans based on botanical account, traditional use, reported bioactive constituents, toxicity, and therapeutic activities. Methods: We used several electronic databases, including scientific data from Pubmed, and Google scholar up to April 3, 2022, incorporating keywords- “Trapa natans,” and “Traditional use of Trapa natans.” Results: The result suggested: a) The plant is used traditionally for treating burning sensation, dipsia, dyspepsia, haemorrhage, diarrhoea, dysentery, leprosy, weariness, inflammation, fractures, pharyngitis, urethrorrhea, bronchitis, and general debility. b) The phytoconstituents found in the plant include cycloucalenol, ursolic acid, ellagic acid, chlorogenic acid, gallic acid, syringic acid, quercetin and 2β, 3α, 23-trihydroxyurs-12-en-28-oic acid. The other phytoconstituents were protein, carbohydrates, starch, flavonoids, and essential vitamins like riboflavin, thiamine, pyridoxine, pantothenic acid, nicotinic acid, vitamin A, vitamin C and D-amylase. c) The plant was studied further for its pharmacological activity in antidiabetic property, antimicrobial potency, anti-inflammatory activity, analgesic activity, immunomodulatory effect, antiulcer activity, anticancer property and nootropic activity. d) Starch obtained from T. natans was also found to have good freeze thaw property, metal chelation property and youghurt stability which could be used for pharmaceutical preparations. e) The oral acute toxicity of hydroalcoholic, ethanolic and methanolic extracts of T. natans was reported to be safe up to a dose of 2000 mg/Kg. Conclusion: The present review suggests that T. natans needs to be explored for evaluation of mechanistic study of the reported activities, preclinical investigations, and evaluation of clinical studies on humans for its pharmacokinetics and pharmacodynamic actions as well as development dose-dependent formulations and routes of administration.

Cancer remains a leading cause of death worldwide, with traditional chemotherapy treatments causing significant side effects. Short synthetic peptides have emerged as a potential alternative due to their unique properties, including selectivity, stability and biocompatibility. Recent research has shown that short peptides can act as effective anticancer agents through their ability to inhibit the COX-2 (Cyclooxegenase-2) enzyme, a key enzyme involved in tumor growth and progression. In particular, short peptides have demonstrated promising results in targeting the tumor microenvironment, disrupting angiogenesis, and inducing apoptosis in cancer cells. This review summarizes the current literature on short peptides as anticancer agents, including their mechanisms of action and future directions for research and development. The results suggest that short peptides hold significant potential as a new class of anticancer agents and warrant further investigation.